文献速递心脑血管急症重症综合管理与镇静镇痛

纤维蛋白原变化与血管内取栓治疗的急性缺血性卒中患者结局相关

The Change in Fibrinogen is Associated with Outcome in Patients with Acute Ischemic Stroke Treated with Endovascular Thrombectomy.
PubMed 文献 · Neurocrit Care · 2023-06-14
一句话结论取栓患者入院高纤维蛋白原血症(>4.5 g/L)与3个月不良结局相关(OR 5.93),Δ纤维蛋白原与结局呈可能U型关联。

该研究连续纳入346例接受血管内取栓的急性缺血性卒中患者,测入院及住院期间纤维蛋白原,计算Δ纤维蛋白原(最高随访值减入院值,正值示升高),以3个月改良Rankin量表>2定义为不良结局。入院高纤维蛋白原血症(>4.5 g/L)与不良结局风险升高相关(OR 5.93,95%CI 1.44-24.41,p=0.014)。Δ纤维蛋白原与结局呈可能U型关联,拐点-0.43 g/L(p=0.04);Δ纤维蛋白原>-0.43 g/L时,纤维蛋白原升高越多不良结局风险越高(OR 1.27,95%CI 1.04-1.54,p=0.016)。

要点

  • 取栓患者入院纤维蛋白原>4.5 g/L与3个月不良结局风险升高相关(OR 5.93,95%CI 1.44-24.41,p=0.014)。
  • Δ纤维蛋白原与3个月结局呈可能U型关联,拐点为-0.43 g/L(p=0.04)。
  • Δ纤维蛋白原>-0.43 g/L时,纤维蛋白原升高越多,不良结局风险越高(OR 1.27,95%CI 1.04-1.54,p=0.016)。
  • Δ纤维蛋白原<-0.43 g/L时,纤维蛋白原下降越多,不良结局风险越高的关联未达统计学显著(OR 0.22,95%CI 0.02-2.48,p=0.219)。
  • 入院纤维蛋白原中位数2.77 g/L(四分位距2.30-3.39 g/L),Δ纤维蛋白原中位数1.38 g/L(四分位距0.27-2.79 g/L)。

适用人群与场景

  • 连续纳入接受血管内取栓治疗的急性缺血性卒中患者,共346例(平均年龄67.4±13.6岁,男性52.31%)。

诊断标准与关键阈值

  • 不良结局定义为3个月改良Rankin量表>2。
  • 高纤维蛋白原血症定义为入院纤维蛋白原>4.5 g/L。
  • Δ纤维蛋白原=最高随访纤维蛋白原-入院纤维蛋白原,正值表示纤维蛋白原水平升高。

研究设计与关键结果

  • 研究类型为连续纳入接受血管内取栓的急性缺血性卒中患者的队列研究,共346例,平均年龄67.4±13.6岁,男性52.31%。
  • 入院纤维蛋白原中位数2.77 g/L(四分位距2.30-3.39 g/L),Δ纤维蛋白原中位数1.38 g/L(四分位距0.27-2.79 g/L)。
  • 入院高纤维蛋白原血症(>4.5 g/L)与不良结局风险升高相关(OR 5.93,95%CI 1.44-24.41,p=0.014)。
  • Δ纤维蛋白原与结局呈可能U型关联,拐点为-0.43 g/L(p=0.04)。
  • Δ纤维蛋白原<-0.43 g/L时,纤维蛋白原下降越多与不良结局风险越高的关联未达统计学显著(OR 0.22,95%CI 0.02-2.48,p=0.219)。
  • Δ纤维蛋白原>-0.43 g/L时,纤维蛋白原升高越多不良结局风险越高(OR 1.27,95%CI 1.04-1.54,p=0.016)。

证据类型、等级与局限

  • 证据类型:连续纳入的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受血管内取栓的患者中,入院高纤维蛋白原血症与3个月功能结局不良相关,Δ纤维蛋白原与3个月不良结局呈可能U型关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Fibrinogen has been identified as a modulator of the coagulation and inflammatory process. There is uncertainty about the relationship between the dynamic profile of fibrinogen levels and its impact on clinical outcomes in patients with acute ischemic stroke treated with endovascular thrombectomy.

METHODS: We consecutively enrolled patients with acute ischemic stroke who underwent endovascular thrombectomy. Fibrinogen was measured on admission and during hospitalization. The change in fibrinogen (Δfibrinogen) was calculated as the highest follow-up fibrinogen minus admission fibrinogen, with a positive Δfibrinogen indicating an increase in fibrinogen level. Functional outcome was assessed by the modified Rankin Scale at 3 months. Poor outcome was defined as modified Rankin Scale > 2.

RESULTS: A total of 346 patients were included (mean age 67.4 ± 13.6 years, 52.31% men). The median fibrinogen on admission was 2.77 g/L (interquartile range 2.30-3.39 g/L). The median Δfibrinogen was 1.38 g/L (interquartile range 0.27-2.79 g/L). Hyperfibrinogenemia (> 4.5 g/L) on admission was associated with an increased risk of poor outcome [odds ratio (OR) 5.93, 95% confidence interval (CI) 1.44-24.41, p = 0.014]. There was a possible U-shaped association of Δfibrinogen with outcomes, with an inflection point of - 0.43 g/L (p = 0.04). When Δfibrinogen was < - 0.43 g/L, a higher decrease in fibrinogen (lower Δfibrinogen value) was associated with a higher risk of poor outcome (OR 0.22, 95% CI 0.02-2.48, p = 0.219). When Δfibrinogen was > - 0.43 g/L, the risk of poor outcome increased with increasing fibrinogen (OR 1.27, 95% CI 1.04-1.54, p = 0.016).

CONCLUSIONS: In patients with endovascular thrombectomy, hyperfibrinogenemia on admission was associated with poor functional outcomes at 3 months, whereas Δfibrinogen was associated with poor 3-month outcomes in a possible U-shaped manner.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Wang C, Cui T, Li S, et al. The Change in Fibrinogen is Associated with Outcome in Patients with Acute Ischemic Stroke Treated with Endovascular Thrombectomy. Neurocrit Care. 2023. PMID: 37316678. doi:10.1007/s12028-023-01768-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。